Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, Nasdaq: NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Intec SRL, an Argentina-based medical device distributor with more than 35 years of experience delivering advanced imaging technologies to healthcare providers nationwide. The Nanox.ARC is ...

Core Insights - Nanox Imaging Ltd will showcase its Nanox.ARC digital tomosynthesis system live in Europe for the first time at the European Congress of Radiology (ECR) from March 4-8, 2026, in Vienna, Austria [1][5] Product Overview - The Nanox.ARC is a CE-marked and FDA-cleared multi-source digital tomosynthesis system that enables 3D imaging at a lower cost and significantly reduced radiation dose compared to traditional CT [2][4] - The system's smaller footprint and simplified installation make it suitable for various European healthcare settings, from major medical centers to community clinics [2][4] Demonstrations and Presentations - Live demonstrations of the Nanox.ARC will occur every 30 minutes at booth 425 during the ECR [3][6] - New clinical data on the role of digital tomosynthesis in lung cancer screening will be presented, along with the TAP2D cloud-enabled image enhancement [3][4] - Oral presentations will cover the potential of digital tomosynthesis in lung cancer screening and the role of AI in CT imaging [5][6] AI Solutions - Nanox will showcase its FDA-cleared AI solutions that analyze routine CT scans for chronic disease indicators, including the AI Cardiac solution (HealthCCSng), AI Bone solution (HealthOST), and AI Liver solution (HealthFLD) [4][9] - Two new AI solutions under development for aortic valve calcification and body composition measurement will also be presented [4] Clinical Studies - Poster presentations will feature new data from the ADOPT study conducted in the UK, highlighting the impact of AI-enabled vertebral fracture identification on clinical workflows and treatment recommendations [4][8] Company Vision - Nanox aims to drive the transition to preventive healthcare by providing an integrated medical imaging and healthcare services platform, combining affordable imaging hardware, advanced AI solutions, and cloud-based software [9][10] - The company's vision includes expanding the reach of medical imaging beyond traditional hospital settings to enhance efficiency and support early disease detection [10][12] Ecosystem Components - The Nanox ecosystem includes the Nanox.ARC imaging system, Nanox.AI for AI-based algorithms, Nanox.CLOUD for data management, and Nanox Health IT for healthcare IT solutions [11]

Core Insights - Nanox Imaging Ltd. has announced a collaboration with Adriamed to expand its commercial presence in Southeast Europe, particularly in Serbia, Montenegro, and Bosnia and Herzegovina [1][2][4] Group 1: Collaboration Details - Adriamed will serve as the exclusive partner for the Nanox.ARC system in the region, managing marketing, distribution, installation, and support [3] - The Nanox.ARC system utilizes advanced 3D imaging technology to provide enhanced diagnostic capabilities at a lower cost compared to traditional systems, and it holds CE Mark certification for commercialization across Europe [2][3] Group 2: Strategic Goals - The collaboration aims to improve access to cost-effective imaging solutions in underserved communities, thereby enhancing patient care and long-term health outcomes [4][6] - Nanox's strategy focuses on leveraging established regional partners to support market penetration and deliver long-term value to healthcare providers [4][6] Group 3: Company Overview - Nanox is dedicated to transforming healthcare through an integrated medical imaging and healthcare services platform, combining affordable imaging hardware, AI solutions, and cloud-based software [5][6] - The company's vision includes expanding the reach of medical imaging beyond traditional hospital settings, enhancing efficiency in imaging workflows, and supporting early disease detection [6][8]

Core Insights - Tempus AI (TEM) is advancing its suite of algorithms and diagnostic software across multiple medical fields, including oncology, digital pathology, radiology, cardiology, and neuropsychology [1][9] Company Developments - Tempus has partnered with Northwestern University's Abrams Center to utilize AI for rapid advancements in Alzheimer's disease research, employing its AI-powered data analytics platform, Lens, to analyze genomic data [2] - The company has received two new FDA 510(k) clearances for its updated Tempus Pixel cardiac imaging platform and ECG–Low EF software, enhancing capabilities in cardiac MR image analysis and identifying patients with reduced left ventricular ejection fraction [3][9] - Strategic acquisitions have bolstered Tempus' position in the market, including the acquisition of Arterys in 2022 for AI tools in imaging data analysis and Paige, which brought a dataset of nearly 7 million clinically annotated pathology slides [4][9] Industry Context - GE HealthCare has launched the Voluson Performance series for women's health ultrasound and is acquiring icometrix for AI-powered brain imaging analysis [5] - NANO-X IMAGING LTD received CE mark certification for its Nanox.ARC system, which generates tomographic images from a single sweep [6] Stock Performance - Tempus' stock has increased by 74% over the past year, significantly outperforming the industry, which saw a decline of 1.5%, while the S&P 500 composite rose by 14.5% [7] Valuation Metrics - Tempus currently has a forward 12-month Price-to-Sales (P/S) ratio of 8.76X, compared to the industry average of 5.77X, indicating a higher valuation [10] Earnings Estimates - The loss per share estimate for Tempus AI for 2025 has remained unchanged over the past 30 days, with estimates at -0.05 for the current quarter, -0.13 for the next quarter, and -0.65 for the current year [11][12]

Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with Althea France to introduce its CE-marked Nanox.ARC system in the French healthcare sector, marking its fourth distribution agreement in Europe [1][2][3] Company Overview - Nanox is focused on advancing medical imaging technology, aiming to drive the transition to preventive healthcare through affordable solutions that leverage AI and proprietary digital X-ray sources [4][5] Partnership Details - Althea France will manage the market introduction, sales, and service of the Nanox.ARC, which is a multi-source digital tomosynthesis system designed to enhance diagnostic capabilities at a lower cost compared to traditional systems [2][3] - The partnership is expected to leverage Althea's established relationships with hospitals and clinics across France, facilitating the introduction of Nanox's imaging platform [3] Market Strategy - France is identified as a strategic market for Nanox, with the partnership expected to expand access to high-quality, affordable imaging services for patients [3] - The collaboration follows previous agreements in Greece, Romania, and the Czech Republic, indicating a growing presence in the European market [1][2]

Core Insights - Nanox's AI solutions, HealthOST and HealthVCF, have been recommended for use in UK NHS hospitals for three years as part of an evaluation of AI in bone disease detection [1][2][3] - The National Institute for Health and Care Excellence (NICE) has included these solutions in an Early Value Assessment to gather evidence on their effectiveness in detecting vertebral fragility fractures [2][3] - The AI technologies aim to enhance the detection of vertebral fragility fractures through opportunistic detection in X-ray images and CT scans [3] Company Overview - Nanox.AI is a subsidiary of Nanox focused on deep-learning medical imaging analytics, targeting chronic and acute diseases [6] - The company aims to drive the transition to preventive healthcare by providing affordable medical imaging technologies [7] - Nanox's ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all designed to improve early detection and treatment [8] Product Details - HealthOST and HealthVCF utilize existing CT scans to support early detection of bone diseases without additional imaging or radiation exposure [4] - These solutions are integrated with existing PACS workflows, allowing real-time identification of clinically significant findings [5] - The tools are expected to improve patient outcomes by enabling timely preventive interventions for conditions like osteoporosis [5]

Core Viewpoint - Nanox Imaging Ltd has announced a registered direct offering of 3,826,530 ordinary shares, expected to generate approximately $15 million in gross proceeds, aimed at strengthening its balance sheet and supporting growth initiatives [1][3]. Group 1: Offering Details - The offering involves the sale of 3,826,530 ordinary shares to a single institutional investor, with gross proceeds anticipated to be around $15 million before expenses [1]. - The closing of the offering is expected on or about November 25, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 3: Company Growth Strategy - The CEO of Nanox stated that the capital raise will enhance the company's balance sheet and accelerate key growth initiatives, including technology advancement, market expansion, and AI infrastructure enhancement [3]. - The company aims to make high-quality medical imaging more accessible globally as it scales deployments and expands capabilities [3]. Group 4: Company Overview - Nanox is focused on transitioning to preventive healthcare through affordable medical imaging technologies, leveraging advanced AI and proprietary digital X-ray sources [6]. - The company's ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all aimed at improving early detection and treatment in healthcare [7].

Core Insights - Nanox Imaging Ltd. reported a net loss of $13.7 million for Q3 2025, slightly higher than the $13.6 million loss in Q3 2024, indicating a marginal increase in losses year-over-year [4] - The company achieved revenue of $3.4 million in Q3 2025, up from $3.0 million in the same period last year, driven by teleradiology services and sales of imaging systems and AI solutions [5] - Nanox is focused on advancing its technologies, expanding its market presence, and enhancing operational efficiency, with significant progress made in these areas during the quarter [3] Financial Performance - The gross loss for Q3 2025 was $2.9 million, with a gross loss margin of 84%, compared to a gross loss of $2.8 million and a margin of 93% in Q3 2024 [6] - Revenue from teleradiology services increased to $3.1 million in Q3 2025 from $2.6 million in Q3 2024, with gross profit from these services rising to $0.8 million, reflecting a gross profit margin of approximately 25% [7] - Revenue from AI solutions decreased to $142 thousand in Q3 2025 from $434 thousand in Q3 2024, with a gross loss of $1.9 million [10] Operational Highlights - The company acquired Vaso Healthcare IT to enhance its AI solutions business and entered multiple global collaborations to accelerate the commercialization of Nanox.ARC and AI solutions [3][8] - Clinical trials have expanded to include Cedars-Sinai in Los Angeles and Olympe Imagerie in Paris, supporting the use of Nanox solutions [8] - Nanox has made strides in the European market, establishing distribution partnerships with EXRAY and Althea France SARL [8] Guidance and Future Outlook - The company anticipates deploying over 100 clinical, demo, and commercial units worldwide by the end of 2025, assuming stable macroeconomic conditions [17] - For the year 2026, Nanox expects revenues to reach $35 million, indicating a positive growth trajectory [19] Liquidity and Capital Resources - As of September 30, 2025, Nanox had total cash and marketable securities of $55.5 million, down from $83.2 million at the end of 2024, with negative cash flow from operations of $30.4 million during the reported period [20] - The company had approximately 65.4 million shares outstanding as of September 30, 2025, an increase from 63.8 million shares at the end of 2024 [22]

Core Viewpoint - Nanox Imaging Ltd has announced the acquisition of VasoHealthcare IT Inc to enhance the deployment of its AI solutions in U.S. healthcare facilities, with the transaction expected to be completed within weeks [1][2]. Company Overview - Nanox is focused on transforming healthcare through affordable medical imaging technologies that leverage advanced AI and proprietary digital X-ray sources [8]. - Vaso Corporation operates in diversified sectors, including healthcare technology and medical devices, with VHC IT being a key player in healthcare information technology [10]. Acquisition Details - The acquisition will involve a total consideration of up to $800,000, which includes a $200,000 cash payment at closing and up to $600,000 in performance-based earnout payments over two years, contingent on revenue retention from existing customers [5]. - VHC IT specializes in healthcare IT implementation, providing services such as systems integration, workflow optimization, and user training, which will be integrated with Nanox's AI solutions [3][4]. Strategic Implications - The integration of VHC IT's operational infrastructure with Nanox.AI's FDA-cleared solutions is expected to accelerate the deployment and adoption of AI technologies in medical imaging, enhancing the customer experience [4][6]. - The acquisition is anticipated to support Nanox's commercial expansion in the U.S. by leveraging VHC IT's expertise and established customer relationships [4][6].

Core Insights - Nanox Imaging Ltd has announced a collaboration with Olympe Imagerie to deploy the Nanox.ARC system at Hospital Privé Jacques Cartier MASSY for lung cancer screening applications, marking a significant step in its European expansion strategy [1][2][5] Company Overview - Nanox is focused on transforming healthcare through affordable medical imaging technologies, leveraging advanced AI and proprietary digital X-ray sources [6] - The Nanox.ARC system is a multi-source digital tomosynthesis system that offers enhanced diagnostic capabilities at a lower cost compared to traditional imaging systems [3] Collaboration Details - The Nanox.ARC system will be utilized in clinical trials at Hospital Privé Jacques Cartier MASSY to evaluate its effectiveness in lung cancer detection and management [2][5] - Olympe Imagerie serves over 400,000 patients annually across multiple centers in the Ile-de-France region, indicating a substantial patient base for the deployment of the Nanox.ARC [4] Market Strategy - France is identified as a key market for Nanox's European expansion, with the collaboration aimed at advancing clinical validation efforts in this region [5] - The deployment of the Nanox.ARC is expected to enhance early detection of lung abnormalities, which is crucial for improving patient outcomes in lung cancer screening [5]